Summaries & Associations of Study Results
TR-057 Beta-thioguanidine deoxyriboside
Target Organs and Levels of Evidence
NTP Technical Report Number 057
Produced from Chemtrack Database 09/19/01
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| BETA-THIOGUANIDINE DEOXYRIBOSIDE 789-61-7 |
02/18/78 | ANTICANCER DRUG | Intraperitoneal Injection R: 0,3.5,7, M: 0,1,4 MG/KG/35 PER GROUP | Southern Research Institute |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: EQUIVOCAL | ZYMBAL GLAND (CARCINOMA) | |||
| FR: POSITIVE | ZYMBAL GLAND (CARCINOMA) | |||
| MM: INADEQUATE STUDY | ||||
| FM: INADEQUATE STUDY | ||||
Web page last updated on February 10, 2006
